Company intelligence / Profile preview

AET BioTech

Hamburg, Hamburg, Germany

Ownership: Private
Employees: ~20
Development stage: Other

Overview

AET BioTech was a biosimilars-focused biotechnology business within the Alfred E. Tiefenbacher Group, with operations referenced in Hamburg, Germany and Malta. The company positioned itself as an independent developer and supplier of biosimilars for branded marketing partners in regulated and emerging markets. Its most visible disclosed program was a biosimilar version of adalimumab (Humira), developed with BioXpress Therapeutics using monoclonal antibody biosimilar technology. Public evidence suggests the Malta legal entity, AET Biotechnology Limited, was later struck off, and AET BioTech does not appear to operate today as an active standalone company.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

BioXpress Therapeutics

Beyond the preview

Go deeper on AET BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AET BioTech.

Explore the full profile